Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.

ABSTRACT:

Background/aims

Chronic hepatitis C (CHC) patients who failed antiviral therapy are at increased risk for hepatocellular carcinoma (HCC). This study assessed the potential role of metformin and statins, medications for diabetes mellitus (DM) and hyperlipidemia (HLP), in reducing HCC risk among these patients.

Methods

We included CHC patients from the T-COACH study who failed antiviral therapy. We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan's cancer registry data from 2003 to 2019. We accounted for death and liver transplantation as competing risks and employed Gray's cumulative incidence and Cox subdistribution hazards models to analyze HCC development.

Results

Out of 2,779 patients, 480 (17.3%) developed HCC post-therapy. DM patients not usin

SUBMITTER: Tsai PC 

PROVIDER: S-EPMC11261235 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature